Cyclacel
Research & Development

Clinical Trials

Cyclacel Pharmaceuticals is currently evaluating the following oncology drug candidates in clinical trials:

  • Fadraciclib (CYC065) is a highly selective, second generation inhibitor of CDK2 and CDK9 that causes apoptotic death of cancer cells at sub-micromolar concentrations and is bioavailable via oral and intravenous routes.

    Learn more about CYC065 trial(s) on ClinicalTrials.gov

  • Sapacitabine (CYC682) is an orally available nucleoside analogue with a novel mechanism, interfering with DNA synthesis by introducing single-strand DNA breaks leading to arrest of cell cycle progression in G2-phase and development of double-strand DNA breaks.

    Learn more about sapacitabine trial(s) on ClinicalTrials.gov

  • CYC140 is a potent inhibitor of PLK-1 with high selectivity. It thwarts the dividing cells to overcome the G2/M transition that leads to apoptosis of the cells.

    Learn more about seliciclib trial(s) on ClinicalTrials.gov

These candidates are experimental drugs under clinical investigation. They are not approved for human use.






 

Research & Development